| Patient | Cleopatra |
|---|---|
| Date of birth | 1997-01-15 |
| Identifiers | MRN HR-AC003-SYN; SSN (made up) 000-03-7095 |
| Document date | 2026-06-23 |
| Author | Nefeli Arvanitis-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Prenatal visit at 25 weeks with the growth scan and glucose challenge. [S]
Cleopatra returns at 25 weeks 0 days. The gastroenteritis three weeks ago settled within two days with oral fluids, and the tightenings stopped with it; she has had none since. Both babies move often. She takes aspirin, the prenatal vitamin, and ferrous sulfate every other day. She has no headache, visual change, swelling of the face or hands, bleeding, leaking fluid, or urinary symptoms. She is still working full days but has moved most of her meetings to the mornings and rests in the afternoon. She had the growth scan and the glucose challenge this morning. [S]
| Element | Detail |
|---|---|
| Gastroenteritis | Resolved within two days; no tightenings since |
| Fetal movement | Both babies moving often |
| Work | Full days with an afternoon rest |
| Tests today | Growth scan, glucose challenge, blood count |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Well |
| Neurological | Negative | No headache or visual change |
| Genitourinary | Negative | No bleeding, leaking fluid, or urinary symptoms |
| Obstetric | Negative | No tightenings or pelvic pressure |
| Psychiatric | Negative | Mood steady; EPDS 7 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Prenatal vitamin containing folic acid 0.4 mg, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-03 | active | S |
| Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other day | One tablet every other morning with water or orange juice, apart from tea, coffee, and calcium | Oral route | 2026-03-03 | active | S |
| Doxylamine succinate 10 mg / pyridoxine hydrochloride 10 mg delayed-release tablet, two tablets by mouth at bedtime | Two tablets at bedtime; may add one in the morning if needed | Oral route | 2026-03-03 to 2026-05-12 | completed | S |
| Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtime | One tablet by mouth at bedtime from 12 weeks until delivery | Oral route | 2026-03-24 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-23 | Body height | 165 | cm | S |
| 2026-06-23 | Body weight | 64.2 | kg | S |
| 2026-06-23 | Body mass index (BMI) [Ratio] | 23.6 | kg/m2 | S |
| 2026-06-23 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-06-23 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-06-23 | Heart rate | 90 | /min | S |
| 2026-06-23 | Respiratory rate | 16 | /min | S |
| 2026-06-23 | Body temperature | 36.7 | Cel | S |
| 2026-06-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-23 | Hemoglobin [Mass/volume] in Blood | 10.9 | g/dL | 10.5-15 g/dL | Normal | S |
| 2026-06-23 | Ferritin [Mass/volume] in Serum or Plasma | 31 | ng/mL | 30-150 ng/mL | Normal | S |
| 2026-06-23 | Platelets [#/volume] in Blood by Automated count | 241 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-23 | Glucose [Mass/volume] in Serum or Plasma --1 hour post 50 g glucose PO | 128 | mg/dL | <=139 mg/dL | Normal | S |
| 2026-06-23 | Fetal Body weight estimated by US | 760 | g | About the 55th centile for 25 weeks | Normal | S |
| 2026-06-23 | Fetal Body weight estimated by US | 720 | g | About the 40th centile for 25 weeks; discordance 5 percent | Normal | S |
| 2026-06-23 | Total score [EPDS] | 7 | {score} | S |
Vital signs recorded on 2026-06-23; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Abdomen | Fundal height 29 cm, consistent with twins at 25 weeks; non-tender |
| Fetal | Scan: estimated weights 760 and 720 g, discordance 5 percent; normal fluid; fetal hearts 144 and 140 per minute |
| Extremities | No edema |
| Urine dipstick | Protein negative |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Uterus larger than dates in early pregnancy: 9 weeks by a certain last menstrual period, with the uterus about 12 to 13 weeks in size; nausea and vomiting heavier than in her first pregnancy; no bleeding; cause not yet known (multiple pregnancy, dating error, fibroids, or molar pregnancy) | resolved | confirmed | O26.841 | S — Synthetic presenting finding anchored to the documented conception in the winter of 41 to 40 BC; it resolves when the ultrasound explains it. |
| Nausea and vomiting of pregnancy, moderate (PUQE score 9); keeping fluids down; no weight loss or ketonuria | resolved | confirmed | O21.9 | S — Synthetic; nausea is common and often heavier in early pregnancy with a large uterus. |
| Iron deficiency anemia in pregnancy: hemoglobin 10.8 g/dL, MCV 79 fL, ferritin 14 ng/mL | active | confirmed | O99.011 | S — Synthetic finding; it echoes no documented diagnosis. |
| Twin pregnancy, dichorionic diamniotic, second pregnancy (gravida 2, para 1): two live fetuses with a thick dividing membrane and a twin-peak (lambda) sign at 11 weeks; dated by her last period, confirmed by the crown-rump lengths | active | confirmed | O30.041 | S — Synthetic modern diagnosis anchored to the documented twins of 40 BC; chorionicity is a modern finding and makes no claim about her real pregnancy. |
| Acute viral gastroenteritis at 22 weeks in a twin pregnancy, with mild dehydration and painless tightenings; no preterm labor (cervical length 39 mm); resolved with oral rehydration | resolved | confirmed | O98.512 | S — Synthetic intercurrent illness at an unscheduled visit, chosen to teach the assessment of tightenings and dehydration in a twin pregnancy; it echoes no documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure and urine protein | Every prenatal visit | Completed today | 108/66 mmHg; urine protein negative |
| Examination | Fetal hearts and fundal height | Every prenatal visit | Completed today | Fetal hearts 144 and 140 per minute; fundal height 29 cm |
| Examination | Weight gain (about 17 to 25 kg for twins from a normal BMI) | Every prenatal visit | Completed today | 64.2 kg, up 6.2 kg since intake |
| Imaging | Growth scan with discordance | Every four weeks from about 20 to 24 weeks in a dichorionic twin pregnancy | Completed today | 760 and 720 g; discordance 5 percent; normal fluid and umbilical artery Doppler |
| Laboratory | Hemoglobin and ferritin | At intake, at the anatomy-scan visit, at 24 to 28 weeks, and in the third trimester | Completed today | Hemoglobin 10.9 g/dL and ferritin 31 ng/mL; platelets 241 |
| Laboratory | Gestational diabetes screen (one-hour 50 g glucose challenge) | At 24 to 28 weeks | Completed today | 128 mg/dL, below the 140 mg/dL threshold |
| Laboratory | Antibody screen and anti-D at 28 weeks | At 28 weeks for RhD-negative patients | Not indicated | RhD positive with a negative antibody screen at intake |
| Survey | Perinatal mood screen (EPDS) | Each trimester | Completed today | 7; item 10 scored 0 |
| Medication safety | Low-dose aspirin | Daily from 12 weeks until delivery; review at every visit | Completed today | Taken nightly; held for one night during the gastroenteritis; no bleeding |
| Medication safety | Tdap vaccine | Once at 27 to 36 weeks in every pregnancy | Due | At the next visit |
| Self-management | Preterm labor warning signs | Every prenatal visit | Completed today | No tightenings since the gastroenteritis; warning signs reviewed |
Goal progress:
Guideline basis: Multifetal Gestations: Twin, Triplet, and Higher-Order Multifetal Pregnancies: ACOG Practice Bulletin, Number 231 (2021); Anemia in Pregnancy: ACOG Practice Bulletin, Number 233 (2021); Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021); ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus (2018); Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 4 (2023)
Follow-up: Prenatal visit with the growth scan at 29 weeks, then every two weeks. Next scheduled visit 2026-08-18: prenatal visit at 33 weeks: growth scan, Tdap, and the delivery plan. [S]